Swedish biotech firm gets green light to take diabetes candidate to clinical phase
![Atrogi CEO Alexandra Ekman Ryding | Photo: Atrogi /PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13848962.ece/ALTERNATES/schema-16_9/doc7k8c89xdktj3nqsya8h.jpg)
Atrogi, a biotech firm based in Sweden, is entering the clinical phase with its new class of molecules for the treatment of type 2 diabetes.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk launches smart insulin pens in the UK
For subscribers